Anti-protein Phosphatase Magnesium-dependent 1A-IgM Levels in Patients with Active Ankylosing Spondylitis: a Potential Biomarker

Overview

Journal Adv Rheumatol

Publisher Biomed Central

Specialty Rheumatology

Date 2024 Sep 13

PMID 39272166

Authors

Yeo-Jin Lee

Eun-Ju Lee

Soo Min Ahn

Seokchan Hong

Ji Seon Oh

Chang-Keun Lee

Bin Yoo

Yong-Gil Kim

Affiliations

Soon will be listed here.

Abstract

Background: Ankylosing spondylitis (AS) has been known to have auto-inflammatory nature; hence, the efficacy of autoantibodies is low. However, studies on autoantibodies are ongoing, with some studies showing associations. Previous studies showed that anti-protein phosphatase magnesium-dependent 1A (PPM1A) IgG was increased in patients with AS and associated with radiographic progression. However, the diagnostic usefulness was limited due to relatively low sensitivity and specificity. This pilot study evaluated the diagnostic utility of anti-PPM1A-IgM and anti-PPM1A-IgG in patients with active AS.

Methods: Serum samples were obtained from the registry cohort of a single tertiary center in Korea. Serum levels of anti-PPM1A-IgG/IgM were measured by direct ELISA. Receiver operating characteristic (ROC) analysis was used to predict the diagnostic sensitivity and specificity of serum anti-PPM1A-IgG/IgM.

Results: Samples were collected from 28 patients with active AS, 16 healthy controls (HCs), and 28 patients with rheumatoid arthritis (RA). Although total serum IgM was lower in the RA and AS groups than in the HC group, anti-PPM1A-IgM was significantly lower in the AS group than in the other groups. In evaluating the diagnostic utility of anti-PPM1A-IgG/IgM for AS patients compared with HCs, the area under the curve (AUC) of anti-PPM1A-IgM was 0.998 (sensitivity 96.4%, specificity 100.0%). When ROC analysis of anti-PPM1A-IgM for AS patients compared with RA patients was conducted, sensitivity was 78.6% and specificity was 71.4%, with an AUC of 0.839.

Conclusion: Decreased anti-PPM1A-IgM levels in AS patients suggests a potential role for anti-PPM1A-IgM in the diagnosis of active AS.

References

Gratacos J, Collado A, Pons F, Osaba M, Sanmarti R, Roque M . Significant loss of bone mass in patients with early, active ankylosing spondylitis: a followup study. Arthritis Rheum. 1999; 42(11):2319-24. DOI: 10.1002/1529-0131(199911)42:11<2319::AID-ANR9>3.0.CO;2-G. View

Braun J, Sieper J . Ankylosing spondylitis. Lancet. 2007; 369(9570):1379-1390. DOI: 10.1016/S0140-6736(07)60635-7. View

Rudwaleit M, Listing J, Brandt J, Braun J, Sieper J . Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor alpha blockers in ankylosing spondylitis. Ann Rheum Dis. 2004; 63(6):665-70. PMC: 1755042. DOI: 10.1136/ard.2003.016386. View

Braun J, Brandt J, Listing J, Zink A, Alten R, Golder W . Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet. 2002; 359(9313):1187-93. DOI: 10.1016/s0140-6736(02)08215-6. View

van der Heijde D, Dijkmans B, Geusens P, Sieper J, DeWoody K, Williamson P . Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum. 2005; 52(2):582-91. DOI: 10.1002/art.20852. View

Haibel H, Rudwaleit M, Brandt H, Grozdanovic Z, Listing J, Kupper H . Adalimumab reduces spinal symptoms in active ankylosing spondylitis: clinical and magnetic resonance imaging results of a fifty-two-week open-label trial. Arthritis Rheum. 2006; 54(2):678-81. DOI: 10.1002/art.21563. View

Ambarus C, Yeremenko N, Tak P, Baeten D . Pathogenesis of spondyloarthritis: autoimmune or autoinflammatory?. Curr Opin Rheumatol. 2012; 24(4):351-8. DOI: 10.1097/BOR.0b013e3283534df4. View

Generali E, Bose T, Selmi C, Voncken J, Damoiseaux J . Nature versus nurture in the spectrum of rheumatic diseases: Classification of spondyloarthritis as autoimmune or autoinflammatory. Autoimmun Rev. 2018; 17(9):935-941. DOI: 10.1016/j.autrev.2018.04.002. View

Baerlecken N, Nothdorft S, Stummvoll G, Sieper J, Rudwaleit M, Reuter S . Autoantibodies against CD74 in spondyloarthritis. Ann Rheum Dis. 2013; 73(6):1211-4. DOI: 10.1136/annrheumdis-2012-202208. View

10.

Tsui F, Tsui H, Las Heras F, Pritzker K, Inman R . Serum levels of novel noggin and sclerostin-immune complexes are elevated in ankylosing spondylitis. Ann Rheum Dis. 2013; 73(10):1873-9. DOI: 10.1136/annrheumdis-2013-203630. View

11.

Li M, Xu X, Su Y, Shao X, Zhou Y, Yan J . A comprehensive overview of PPM1A: From structure to disease. Exp Biol Med (Maywood). 2021; 247(6):453-461. PMC: 8943326. DOI: 10.1177/15353702211061883. View

12.

Strovel E, Wu D, Sussman D . Protein phosphatase 2Calpha dephosphorylates axin and activates LEF-1-dependent transcription. J Biol Chem. 2000; 275(4):2399-403. DOI: 10.1074/jbc.275.4.2399. View

13.

Duan X, Liang Y, Feng X, Lin X . Protein serine/threonine phosphatase PPM1A dephosphorylates Smad1 in the bone morphogenetic protein signaling pathway. J Biol Chem. 2006; 281(48):36526-32. DOI: 10.1074/jbc.M605169200. View

14.

Kim Y, Sohn D, Zhao X, Sokolove J, Lindstrom T, Yoo B . Role of protein phosphatase magnesium-dependent 1A and anti-protein phosphatase magnesium-dependent 1A autoantibodies in ankylosing spondylitis. Arthritis Rheumatol. 2014; 66(10):2793-2803. PMC: 4198528. DOI: 10.1002/art.38763. View

15.

Ravandi A, Boekholdt S, Mallat Z, Talmud P, Kastelein J, Wareham N . Relationship of IgG and IgM autoantibodies and immune complexes to oxidized LDL with markers of oxidation and inflammation and cardiovascular events: results from the EPIC-Norfolk Study. J Lipid Res. 2011; 52(10):1829-36. PMC: 3173004. DOI: 10.1194/jlr.M015776. View

16.

Tsimikas S, Brilakis E, Lennon R, Miller E, Witztum J, McConnell J . Relationship of IgG and IgM autoantibodies to oxidized low density lipoprotein with coronary artery disease and cardiovascular events. J Lipid Res. 2006; 48(2):425-33. DOI: 10.1194/jlr.M600361-JLR200. View

17.

Sieper J, Rudwaleit M, Khan M, Braun J . Concepts and epidemiology of spondyloarthritis. Best Pract Res Clin Rheumatol. 2006; 20(3):401-17. DOI: 10.1016/j.berh.2006.02.001. View

18.

Bhatia K, Prasad M, Barnish G, Koki G . Antigen and haplotype frequencies at three human leucocyte antigen loci (HLA-A, -B, -C) in the Pawaia of Papua New Guinea. Am J Phys Anthropol. 1988; 75(3):329-40. DOI: 10.1002/ajpa.1330750304. View

19.

Alexeeva L, Krylov M, Vturin V, Mylov N, Erdesz S, Benevolenskaya L . Prevalence of spondyloarthropathies and HLA-B27 in the native population of Chukotka, Russia. J Rheumatol. 1994; 21(12):2298-300. View

20.

Khan M, Braun W, Kushner I, Grecek D, Muir W, Steinberg A . HLA B27 in Ankylosing Spondylitis: Differences in Frequency and Relative Risk in American Blacks and Caucasians. J Rheumatol. 2023; 50(1):39-43. View